Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy

BACKGROUND: Inhibitors of immune checkpoint programmed cell death protein 1 (PD-1) receptor on T cells have shown remarkable clinical outcomes in metastatic melanoma. However, most patients are resistant to therapy. Production of extracellular adenosine, via CD73-mediated catabolism of AMP, contribu...

詳細記述

保存先:
書誌詳細
出版年:J Immunother Cancer
主要な著者: Turiello, Roberta, Capone, Mariaelena, Giannarelli, Diana, Morretta, Elva, Monti, Maria Chiara, Madonna, Gabriele, Mallardo, Domenico, Festino, Lucia, Azzaro, Rosa, Levesque, Mitchell P, Imhof, Laurence, Weide, Benjamin, Amaral, Teresa, Chevrier, Marc, Sucker, Antje, Rutkowski, Piotr, Schadendorf, Dirk, Lebbe, Celeste, Luke, Jason John, Wistuba-Hamprecht, Kilian, Dummer, Reinhard, Pinto, Aldo, Morello, Silvana, Ascierto, Paolo A
フォーマット: Artigo
言語:Inglês
出版事項: BMJ Publishing Group 2020
主題:
Immunotherapy Biomarkers
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7759961/
https://ncbi.nlm.nih.gov/pubmed/33361405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001689
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料